TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32129681
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus rivaroxaban (2.5 mg b.i.d.)
Study: 32129681
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 mg q.d.)
Study: 32947455
Drug: Guided Exercise
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided Exercise Therapy (GET)
Study: 35116266
Drug: Extended field-IMRT
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended field-IMRT with concurrent cisplatin chemotherapy (40 mg/m2)
Study: 35116266
Drug: Pelvic-IMRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic-IMRT with concurrent cisplatin chemotherapy (40 mg/m2)
Study: 32843084
Drug: Fire needle
Normalized name: Fire Out
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fire needle control therapy
Study: 33347022
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine for 8 weeks
Study: 34826819
Drug: NSAIDs (parecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs (parecoxib injection and subsequent loxoprofen tablets)
Study: 32960662
Drug: postoperative radio‐chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: postoperative radio‐chemotherapy (p‐RTCT)
Study: 33241466
Drug: 1.5% levofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% levofloxacin with 0.1% fluorometholone administered four times a day
Study: 33241466
Drug: sixfold dilution
Approvals — FDA: no, EMA: no, PMDA: no
Description: sixfold dilution of polyvinyl alcohol iodine (PAI) solution with 0.1% fluorometholone four times a day
Study: 35121271
Drug: Face to
Normalized name: NAIR FACE TOP CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face to face (FtF) therapy
Study: 35121271
Drug: Digital (dCBT-I)
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital (dCBT-I) therapy
Study: 33303654
Drug: RAAS inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAAS inhibitors (RAASi)
Study: 33023491
Drug: 0.04 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.04 mg/kg neostigmine
Study: 33023491
Drug: 0.02 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02 mg/kg neostigmine
Study: 35700594
Drug: Taurine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurine (1.5 g)
Study: 35700594
Drug: Placebo (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1.5 g of starch)
Study: 35484039
Drug: MucoRice-CTB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MucoRice-CTB vaccine (6-g dose)
Study: 33846198
Drug: standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard of care (SOC) with chemotherapy
Study: 35532915
Drug: Compound intervention
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound intervention with digital scales, electronic pill bottles, and regret lottery incentives ($1.40 expected daily value)
Study: 35532915
Drug: Compound intervention
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound intervention
Study: 36352602
Drug: Yoga as
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga as a complementary treatment for epilepsy
Study: 35271811
Drug: unilateral intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: unilateral intravitreal AAV2(Y444,500,730F)‐P1ND4v2 injection (higher doses)
Study: 35271811
Drug: unilateral intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: unilateral intravitreal AAV2(Y444,500,730F)‐P1ND4v2 injection (lower doses)
Study: 35271811
Drug: unilateral intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: unilateral intravitreal AAV2(Y444,500,730F)‐P1ND4v2 injection
Study: 34274079
Drug: Caffeine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (300 mg) given 45 minutes before training
Study: 35799365
Drug: Capsaicin 8%
Normalized name: CAPSAICIN 8% PATCH KIT,4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin 8% Patch (C8P)
Study: 35799365
Drug: Control low
Normalized name: Surestep Control Low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control low dose Capsaicin 0.025% patch (CON)
Study: 36285763
Drug: Imported doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imported doses from Héma-Québec
Study: 36285763
Drug: Transferred doses
Normalized name: SET,TRANSFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transferred doses between CBS regional distribution centers
Study: 34101389
Drug: Three-weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three-weekly cisplatin 100 mg/m2
Study: 35954612
Drug: Hedonic aroma
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hedonic aroma (essential oils) during chemotherapy (inhalation during T1, T2, T3)
Study: 33619780
Drug: Calcipotriol 50
Normalized name: Calcipotriol 50 microgram/g cutaneous cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol 50 µg/g plus betamethasone dipropionate 0.5 mg/g cutaneous foam (Cal/BD foam)
Study: 33177798
Drug: SPMC ½
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPMC ½ dose × 2
Study: 33177798
Drug: SPMC 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPMC 1 dose × 2
Study: 35607733
Drug: Sequential injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential injection of 1.5 mL of 0.5% hyperbaric bupivacaine with 15 μg of fentanyl followed by 1.5 mL of 0.5% isobaric bupivacaine (HIB group)
Study: 35607733
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL of 0.5% hyperbaric bupivacaine mixed with 15 μg of fentanyl citrate (HB group)
Study: 33307206
Drug: Yoga program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga program (12-week, 2x weekly/90-minute sessions)
Study: 33307206
Drug: Education control
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education control group (1x weekly/60-minute lectures)
Study: 35101266
Drug: Four-dose schedule
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-dose schedule (0–7–21–360)
Study: 35101266
Drug: Three-dose schedule
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dose schedule (days 0–30–360)
Study: 35101266
Drug: Four-dose schedule
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-dose schedule (0–30–90–360)
Study: 33414239
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg twice daily for 16 weeks
Study: 33414239
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for 16 weeks
Study: 33414239
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg twice daily for 12 months
Study: 33414239
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for 12 months
Study: 35361556
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity intervention (12-month duration, delivered twice weekly for the first 12 weeks, then once weekly; included cardiovascular, strength, balance, and flexibility exercises)
Study: 34580251
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation (OAC) therapy
Study: 36158133
Drug: Precision health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Precision health education guidance after ESWL treatment
Study: 32555026
Drug: High-Intensity Aerobic
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Aerobic Interval Training (HIIT) in addition to treatment as usual (n = 13)
Study: 32555026
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (n = 8)
Study: 35216854
Drug: Routine prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine prescription education
Study: 32842819
Drug: Endobronchial valve
Normalized name: VALVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endobronchial valve therapy
Study: 32726422
Drug: MVA‐BN‐RSV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA‐BN‐RSV vaccine (single dose)
Study: 32726422
Drug: MVA‐BN‐RSV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA‐BN‐RSV vaccine (12-month booster dose)
Study: 36278483
Drug: DEN-181 (medium
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEN-181 (medium dose)
Study: 36278483
Drug: DEN-181 (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEN-181 (high dose)
Study: 36278483
Drug: DEN-181 (low/medium
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEN-181 (low/medium doses)
Study: 33905738
Drug: Medication reconciliation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication reconciliation via a patient portal
Study: 33905738
Drug: Medication reconciliation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication reconciliation by a pharmacy technician (usual care)
Study: 32505861
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + goserelin (C + G)
Study: 32505861
Drug: Chemotherapy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy only (C)
Study: 32505861
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (C±G)
Study: 32321353
Drug: Community treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community treatment as usual (Control)
Study: 34697951
Drug: Distal approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distal approach (DA) for local corticosteroid injection (LCI)
Study: 34697951
Drug: Proximal approach
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proximal approach (PA) for local corticosteroid injection (LCI)
Study: 33106117
Drug: Surgery, chemotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery, chemotherapy, and molecularly targeted agents (bevacizumab and PARP inhibitors)
Study: 35044844
Drug: Intranasal orexin
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal orexin A (500 nmol)
Study: 35044844
Drug: Intranasal orexin
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal orexin A
Study: 32894278
Drug: Miltefosine and
Normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miltefosine and topical GM‐CSF (M + GM)
Study: 35843520
Drug: Tralokinumab monotherapy
Normalized name: tralokinumab
DrugBank: Tralokinumab (DB12169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tralokinumab monotherapy (ECZTRA 1 + 2)
Study: 35403380
Drug: Azvudine and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azvudine and symptomatic treatment (FNC group)
Study: 35403380
Drug: Standard antiviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiviral and symptomatic treatment (control group)
Study: 32702878
Drug: Low-level light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level light therapy (LLLT) using a helmet-type device
Study: 34313686
Drug: 7-day antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day antibiotic therapy (ciprofloxacin or trimethoprim/sulfamethoxazole)
Study: 34313686
Drug: 14-day antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day antibiotic therapy (ciprofloxacin or trimethoprim/sulfamethoxazole)
Study: 33157425
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg fast-release melatonin
Study: 34487412
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg rifaximin 3 times/d plus 30-45 mL lactulose 3 times/d
Study: 33567859
Drug: 1% high-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% high-molecular-weight hyaluronic acid (1 mL)
Study: 33567859
Drug: 1% low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% low-molecular-weight hyaluronate (1 mL)
Study: 32138344
Drug: 3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/day oat beta-glucans
Study: 35948382
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of prednisolone for 10 days
Study: 35948382
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo treatment
Study: 33971105
Drug: Neuropeptide Y
Normalized name: Neuropeptide Y
DrugBank: Neuropeptide Y (DB11788)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuropeptide Y hormone in the ischemic phase
Study: 35749352
Drug: Treatment cream
Normalized name: Acne Treatment Cream
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment cream (inert unscented lotion) administered by a provider
Study: 34882581
Drug: Adjuvant vaccines
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant vaccines (given to all patients)
Study: 35616047
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg methadone (MET)
Study: 35616047
Drug: 7.5 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 μg/kg dexmedetomidine (D7)
Study: 35616047
Drug: 10 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg/kg dexmedetomidine (D10)
Study: 35616047
Drug: 7.5 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 μg/kg dexmedetomidine and 0.2 mg/kg methadone (DM7)
Study: 35616047
Drug: 10 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg/kg dexmedetomidine and 0.2 mg/kg methadone (DM10)
Study: 35616047
Drug: Low-dose dexmedetomidine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dexmedetomidine (7.5 µg/kg)
Study: 33681993
Drug: Rhinovirus A16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhinovirus A16 (3 different doses)
Study: 33983765
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day pregabalin (EXP 1)
Study: 33983765
Drug: 450 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg/day pregabalin (EXP 2)
Study: 33860850
Drug: Probiotics (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (2 g for 30 days)
Study: 33860850
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 g whey powder for 30 days)
Study: 34372971
Drug: Trastuzumab maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab maintenance therapy
Study: 34159386
Drug: Monthly smoking
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly smoking days for JHS girls
Study: 35069955
Drug: Zolpidem 10
Normalized name: zolpidem 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 10 mg (S group)
Study: 32852294
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine with 150 µg epinephrine, 2 mL of 8.4% bicarbonate, and 100 µg fentanyl (LEBF)
Study: 32472742
Drug: NEPA (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEPA (single oral dose)
Study: 33857782
Drug: UVC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVC treatment
Study: 33863564
Drug: 100μg selenium
Normalized name: SELENIUM 100MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100μg selenium tablet twice a day for 6 months
Study: 33863564
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets (100μg of starch) twice a day for 6 months
Study: 35743485
Drug: Photobiomodulation (PBM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation (PBM) treatment with a diode laser (810 nm, 6 J/cm2) for 6 weeks (1 session per week)
Study: 35743485
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control (simulated treatment)
Study: 32744555
Drug: Phenolic compounds
Normalized name: Phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenolic compounds in skin and flesh of apples
Study: 35861012
Drug: Be a
Normalized name: Tube Attaching Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Be a Mom, a self‐guided web‐based cognitive behavioral therapy intervention
Study: 33528919
Drug: Lifestyle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle intervention plus liraglutide 3.0 mg
Study: 32374724
Drug: Integrated depression
Normalized name: Nerve depressants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated depression screening and treatment program (Friendship Bench therapy and antidepressants)
Study: 36763899
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) injections
Study: 36034448
Drug: YPEG-rhGH 100
Normalized name: rhGH
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: YPEG-rhGH 100 μg/kg/week
Study: 36034448
Drug: YPEG-rhGH 120
Normalized name: rhGH
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: YPEG-rhGH 120 μg/kg/week
Study: 36034448
Drug: YPEG-rhGH 140
Normalized name: rhGH
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: YPEG-rhGH 140 μg/kg/week
Study: 36034448
Drug: Daily rhGH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily rhGH 35 μg/kg/day
Study: 36034448
Drug: YPEG-rhGH (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: YPEG-rhGH (all doses)
Study: 33099855
Drug: Erector spinae
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erector spinae plane (ESP) block with 30 ml 0.25% bupivacaine at the T8 level
Study: 33099855
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 50 mg of dexketoprofen trometamol (NSAID)
Study: 32899959
Drug: PRP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP therapy
Study: 33687145
Drug: Purple potato
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purple potato extract rich in acylated anthocyanins (152 mg) and hydroxycinnamic acid conjugates (140 mg)
Study: 616542428
Drug: Glycerol (G)
DrugBank: Glycerin (DB09462)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycerol (G)
Study: 39287532
Drug: Ranibizumab 0.5
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.5 mg pro re nata
Study: 32192496
Drug: LIG once
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LIG once weekly (QW)
Study: 32192496
Drug: LIG twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIG twice weekly (BW)
Study: 32192496
Drug: Enrofloxacin and
Normalized name: ENROFLOXACIN 5 mg in 1 mL / SILVER SULFADIAZINE 10 mg in 1 mL AURICULAR (OTIC) EMULSION [Enrofloxacin and Silver Sulfadiazine Otic Emulsion]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrofloxacin and silver sulfadiazine twice daily (C)
Study: 35951253
Drug: 1-hour training
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour training in stimulant diversion prevention
Study: 32029903
Drug: Naltrexone (NTX)
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone (NTX) treatment for at least three months
Study: 35012827
Drug: BTA injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTA injections into the subjacent orbicularis oris muscle (4 points group)
Study: 35012827
Drug: BTA injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTA injections into the bilateral nasolabial fold region (6 points group)
Study: 33342522
Drug: Additional $40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional $40 in monthly SNAP benefits per child under age 5 years (treatment group)
Study: 32437787
Drug: Heithersay classification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heithersay classification and treatment decision by independent evaluators.
Study: 34621707
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg twice a day
Study: 33274528
Drug: Maximal removal
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal removal torque evaluated at the end of treatment in Group 3.
Study: 33676294
Drug: Prior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior therapy
Study: 34315379
Drug: Instructions of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instructions of Daily Care (IDC)
Study: 32065415
Drug: Oral controlled-release
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral controlled-release ketamine tablets (60, 120, or 240 mg)
Study: 32682556
Drug: Norepinephrine 6
Normalized name: NOREPINEPHRINE 64MCG/ML/D5 INJ BAG 250ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine 6 μg ml−1
Study: 32682556
Drug: Phenylephrine 100
Normalized name: phenylephrine 100 mcg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine 100 μg ml−1
Study: 33164784
Drug: Garcinia cambogia
Normalized name: Garcinia Cambogia Fruit
DrugBank: Garcinia gummi-gutta fruit (DB14365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garcinia cambogia extract (GCE)/(−) – hydroxycitric acid (HCA) 1500/750 mg under fasted condition
Study: 33164784
Drug: Garcinia cambogia
Normalized name: Garcinia Cambogia Fruit
DrugBank: Garcinia gummi-gutta fruit (DB14365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garcinia cambogia extract (GCE)/(−) – hydroxycitric acid (HCA) 1500/750 mg under fed condition after a high calorie breakfast (600 calories)
Study: 32833285
Drug: AST-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST-guided therapy (bismuth-containing quadruple therapy guided by antimicrobial susceptibility testing)
Study: 32833285
Drug: PMH-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMH-guided therapy (personal medication history-guided therapy)